Allogene Therapeutics Reports Q2 2026 Results

What Happened

• Allogene Therapeutics, Inc. (ALLO) filed an 8-K on August 12, 2026 (Item 2.02) to provide a corporate update and announce its financial results for the quarter ended June 30, 2026. The company attached a press release as Exhibit 99.1, which is incorporated by reference into the filing. The report is signed by President & CEO Zachary Roberts, M.D., Ph.D.

Key Details

• Filing date: August 12, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Quarter covered: Quarter ended June 30, 2026 (Q2 2026).
• Press release with the financial results is attached as Exhibit 99.1 to the 8-K.
• Cover page is formatted in Inline XBRL (Exhibit 104).

Why It Matters

• This 8-K signals that Allogene has released its latest quarterly earnings and a corporate update; those materials will contain the company’s reported revenue, expenses, net results and any commentary on business progress or outlook.
• For investors, the press release (Exhibit 99.1) is the primary source for the actual financial figures and management commentary—review it to assess revenue, profitability, cash runway, and any guidance or strategic updates.
• Next steps for retail investors: read the attached press release on EDGAR or the company’s Investor Relations page, and watch for any follow-up SEC filings, earnings call, or investor presentation that may provide more detail. Keywords: earnings, revenue, quarterly results, CEO.